Question · asked by 1 review

CHLORPROMAZINE LOW DOSE (≤ 400 mg/day) vs HIGH DOSE (> 800 mg/day ‐ all medium term): Global state: No clinically significant response (as defined by the original studies)

Population
schizophrenia
Intervention
CHLORPROMAZINE LOW DOSE (≤ 400 mg/day)
Comparison
HIGH DOSE (> 800 mg/day ‐ all medium term)
Outcome
Global state: No clinically significant response (as defined by the original studies)

CHLORPROMAZINE LOW DOSE (≤ 400 mg/day) probably leads to higher global state: no clinically important improvement ‐ medium term compared with HIGH DOSE (> 800 mg/day ‐ all medium term) (moderate certainty).

What each review found

Current versions only
FindingEffectStudiesGRADE certainty
CHLORPROMAZINE LOW DOSE (≤ 400 mg/day) vs HIGH DOSE (> 800 mg/day ‐ all medium term)
Global state: no clinically important improvement ‐ medium term · patients with people with schizophrenia
CHLORPROMAZINE LOW DOSE (≤ 400 mg/day) probably leads to higher global state: no clinically important improvement ‐ medium term compared with HIGH DOSE (> 800 mg/day ‐ all medium term) (moderate certainty).
Chlorpromazine dose for people with schizophrenia (2017) · Cochrane Headline outcomes only
RR 1.13 [1.01, 1.25]1 study · 416 participantsModerate

Findings are shown side by side, never pooled across reviews.

The reviews

ReviewSearched up toIncluded studiesAMSTAR 2
Chlorpromazine dose for people with schizophrenia
2017 · Cochrane Headline outcomes only
Not reportedNot extractedNot assessed
How reviews are matched to this question

Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.